Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 61.2 Million PLN | 665.12% |
| 2022 | 7.99 Million PLN | 193.86% |
| 2021 | 2.72 Million PLN | -50.58% |
| 2020 | 5.5 Million PLN | -38.43% |
| 2019 | 8.94 Million PLN | 182.03% |
| 2018 | 3.17 Million PLN | -69.77% |
| 2017 | 10.49 Million PLN | 12.14% |
| 2016 | 9.35 Million PLN | -61.77% |
| 2015 | 24.47 Million PLN | 32.14% |
| 2014 | 18.52 Million PLN | 135.25% |
| 2013 | 7.87 Million PLN | 354.47% |
| 2012 | 1.73 Million PLN | -90.16% |
| 2011 | 17.61 Million PLN | -4.58% |
| 2010 | 18.45 Million PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 59.89 Million PLN | 1.75% |
| 2024 Q2 | 61.39 Million PLN | -2.18% |
| 2023 Q2 | 15.17 Million PLN | 81.06% |
| 2023 Q4 | 61.2 Million PLN | 50.66% |
| 2023 FY | 61.2 Million PLN | 665.12% |
| 2023 Q3 | 40.62 Million PLN | 167.73% |
| 2023 Q1 | 8.38 Million PLN | 4.76% |
| 2022 Q3 | 2.55 Million PLN | 1.79% |
| 2022 FY | 7.99 Million PLN | 193.86% |
| 2022 Q2 | 2.51 Million PLN | -10.47% |
| 2022 Q4 | 7.99 Million PLN | 212.71% |
| 2022 Q1 | 2.8 Million PLN | 3.12% |
| 2021 Q3 | 2.81 Million PLN | 0.0% |
| 2021 Q4 | 2.72 Million PLN | -3.13% |
| 2021 FY | 2.72 Million PLN | -50.58% |
| 2021 Q1 | 5.76 Million PLN | 4.74% |
| 2020 Q2 | 8.74 Million PLN | -1.01% |
| 2020 Q4 | 5.5 Million PLN | -1.92% |
| 2020 FY | 5.5 Million PLN | -38.43% |
| 2020 Q3 | 5.61 Million PLN | -35.77% |
| 2020 Q1 | 8.83 Million PLN | -1.27% |
| 2019 Q3 | 9.06 Million PLN | 209.63% |
| 2019 Q4 | 8.94 Million PLN | -1.29% |
| 2019 Q2 | 2.92 Million PLN | -6.69% |
| 2019 Q1 | 3.13 Million PLN | -1.1% |
| 2019 FY | 8.94 Million PLN | 182.03% |
| 2018 Q3 | 3.31 Million PLN | -66.25% |
| 2018 Q1 | 10.19 Million PLN | -2.8% |
| 2018 Q4 | 3.17 Million PLN | -4.17% |
| 2018 FY | 3.17 Million PLN | -69.77% |
| 2018 Q2 | 9.8 Million PLN | -3.84% |
| 2017 Q4 | 10.49 Million PLN | 20.78% |
| 2017 FY | 10.49 Million PLN | 12.14% |
| 2017 Q2 | 8.95 Million PLN | 0.11% |
| 2017 Q3 | 8.68 Million PLN | -3.01% |
| 2017 Q1 | 8.94 Million PLN | -4.37% |
| 2016 Q4 | 9.35 Million PLN | 0.0% |
| 2016 FY | 9.35 Million PLN | -61.77% |
| 2016 Q2 | - PLN | 0.0% |
| 2016 Q3 | - PLN | 0.0% |
| 2016 Q1 | - PLN | -100.0% |
| 2015 Q4 | 24.47 Million PLN | 0.0% |
| 2015 FY | 24.47 Million PLN | 32.14% |
| 2015 Q3 | - PLN | 0.0% |
| 2015 Q2 | - PLN | 0.0% |
| 2015 Q1 | - PLN | -100.0% |
| 2014 FY | 18.52 Million PLN | 135.25% |
| 2014 Q1 | 7.37 Million PLN | -6.27% |
| 2014 Q2 | 6.97 Million PLN | -5.5% |
| 2014 Q4 | 18.52 Million PLN | 189.88% |
| 2014 Q3 | 6.38 Million PLN | -8.37% |
| 2013 Q3 | 802.14 Thousand PLN | -31.69% |
| 2013 Q4 | 7.87 Million PLN | 881.57% |
| 2013 Q2 | 1.17 Million PLN | -24.06% |
| 2013 Q1 | 1.54 Million PLN | -10.74% |
| 2013 FY | 7.87 Million PLN | 354.47% |
| 2012 Q4 | 1.73 Million PLN | 0.0% |
| 2012 FY | 1.73 Million PLN | -90.16% |
| 2011 FY | 17.61 Million PLN | -4.58% |
| 2010 FY | 18.45 Million PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -80077.643% |
| BIOTON S.A. | 12.67 Million PLN | -382.78% |
| Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | -4807.939% |
| Mabion S.A. | 2.94 Million PLN | -1976.052% |
| Molecure S.A. | 4.97 Million PLN | -1129.988% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 114 Thousand PLN | -53585.965% |
| Poltreg S.A. | 7.8 Million PLN | -684.54% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | -376.206% |
| Ryvu Therapeutics S.A. | 365 Thousand PLN | -16667.671% |
| Urteste S.A. | 312 Thousand PLN | -19516.026% |